Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | SI | P14410 | 3/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.39 |
| ▸ | NQO2 | P16083 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31399980 | 1.00 | TDP1 (0.52) | TDP1MAPTRAB9AMAPK1L3MBTL1 | |
| SCHEMBL14764520 | 0.88 | MAPT (0.44) | TDP1MAPTRAB9AMAPK1L3MBTL1 | |
| SCHEMBL14764415 | 0.88 | MAPT (0.44) | TDP1MAPTRAB9AMAPK1L3MBTL1 | |
| SCHEMBL31643056 | 0.84 | RAB9A (0.53) | MAPTRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL20475325 | 0.84 | RAB9A (0.53) | MAPTRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL14842553 | 0.80 | KDM4E (0.62) | TDP1MAPTRAB9AMAPK1L3MBTL1 | |
| SCHEMBL183009 | 0.77 | NQO2 (0.57) | MAPTRAB9AMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL8604288 | 0.77 | MAPT (0.52) | MAPTRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL7527351 | 0.77 | TDP1 (0.56) | TDP1MAPTRAB9AMAPK1ALDH1A1 | |
| SCHEMBL23886102 | 0.76 | DRD4 (0.46) | MAPTRAB9AMAPK1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3807270-B1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-09-13 | — | — | EP | disclosed |
| EP-3807270-B1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3856737-B1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-17 | — | — | EP | disclosed |
| EP-3856737-B1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-17 | — | — | EP | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| US-8673908-B2 | Kynurenine production inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8435994-B2 | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435994-B2 | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120232086-A1 | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232086-A1 | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2374802-A1 | KYNURENINE PRODUCTION INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2011060207-A1 | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-0045423-B1 | PROCESS FOR THE ALPHA-HALOGENATION OF POSSIBLY SUBSTITUTED METHYL AROMATICS | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| EP-0045423-A1 | Process for the alpha-halogenation of possibly substituted methyl aromatics | BAYER AG (DE) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CDK1, CSNK1A1, CSNK1G1 | TDP1 292/4885MAPT 286/4885RAB9A 3351/4885 |
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | PDE6D, PDE6H, ADRA1D | TDP1 1657/4885MAPT 1179/4885RAB9A 640/4885 |
| US-20120232086-A1 | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | TDP1 1037/4885MAPT 1754/4885RAB9A 994/4885 |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | SSB, UACA, HLA-DRB1 | TDP1 2722/4885MAPT 4654/4885RAB9A 248/4885 |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | TDP1 2717/4885MAPT 3885/4885RAB9A 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.